Hasmukh Chudgar has recently transferred the management of a company with USD 2.3 billion in revenue to his sons, Nimish and Binish Chudgar.
Hasmukh Chudgar, the founder of Intas Pharmaceuticals, a generics maker, is among India’s most seasoned billionaires. With a low-profile demeanor, Hasmukh Chudgar established Intas Pharmaceuticals in 1977. According to Forbes, the combined net worth of Hasmukh Chudgar and his family is USD 7.6 billion.
Hasmukh Chudgar, who obtained his Bachelor’s degree in Pharmacy from Gujarat University, has recently entrusted the management of a USD 2.3 billion revenue company to his sons, Nimish and Binish Chudgar. Currently serving as the Executive Chairman of Intas Pharma, Hasmukh Chudgar oversees the company’s operations. Intas Pharma operates a total of 15 factories, with 10 located in India and others situated in Europe and Mexico.
In 2019, Intas made waves with the introduction of Eleftha, an affordable drug for the treatment of breast cancer. This development garnered significant attention as Eleftha, manufactured by Intas, bears similarity to Herceptin, a drug produced by Roche.
In 2022, Abu Dhabi Investment Authority acquired a 3% stake in Intas from Temasek, a Singapore-based firm. Europe and India serve as the largest markets for Intas, driving the company’s growth and success.
Hasmukh Chudgar possesses extensive experience in the pharmaceutical industry. Presently, he serves as a trustee of the Intas Welfare Trust, established to provide assistance to the company’s employees.
The Chudgars, known for their modesty, possess an entrepreneurial spirit and tremendous drive. They are deeply passionate about the pharmaceutical field, dedicating their thoughts, conversations, and efforts to it, yet they choose to maintain a low-profile presence.
